. Cardiac remodeling and contractile function in acid ␣-glucosidase knockout mice. Physiol Genomics 5: 171-179, 2001.-Pompe's disease is an autosomal recessive and often fatal condition, caused by mutations in the acid ␣-glucosidase gene, leading to lysosomal glycogen storage in heart and skeletal muscle. We investigated the cardiac phenotype of an acid ␣-glucosidase knockout (KO) mouse model. Left ventricular weight-to-body weight ratios were increased 6.3 Ϯ 0.8 mg/g in seven KO compared with 3.2 Ϯ 0.2 mg/g in eight wild-type (WT) mice (P Ͻ 0.05). Echocardiography under ketamine-xylazine anesthesia revealed an increased left ventricular (LV) wall thickness (2.17 Ϯ 0.16 in KO vs. 1.18 Ϯ 0.10 mm in WT mice, P Ͻ 0.05) and a decreased LV lumen diameter (2.50 Ϯ 0.32 in KO vs. 3.21 Ϯ 0.14 mm in WT mice, P Ͻ 0.05), but LV diameter shortening was not different between KO and WT mice. The maximum rate of rise of left ventricular pressure (LV dP/dtmax) was lower in KO than in WT mice under basal conditions (2,720 Ϯ 580 vs. 4,440 Ϯ 440 mmHg/s) and during dobutamine infusion (6,220 Ϯ 800 vs. 8,730 Ϯ 790 mmHg/s, both P Ͻ 0.05). Similarly, during isoflurane anesthesia LV dP/dtmax was lower in KO than in WT mice under basal conditions (5,400 Ϯ 670 vs. 8,250 Ϯ 710 mmHg/s) and during norepinephrine infusion (10,010 Ϯ 1,320 vs. 14,710 Ϯ 220 mmHg/s, both P Ͻ 0.05). In conclusion, the markedly increased LV weight and wall thickness, the encroachment of the LV lumen, and LV dysfunction reflect cardiac abnormalities, although not as overt as in humans, of human infantile Pompe's disease and make these mice a suitable model for further investigation of pathophysiology and of novel therapies of Pompe's disease. contractility; echocardiography; glycogen storage disease type II; lysosomal; metabolic disorder POMPE'S DISEASE or glycogen storage disease type II (GSD II) is an autosomal recessive and often fatal disease caused by mutations in the acid ␣-glucosidase gene (16). The resultant deficiency of acid ␣-glucosidase activity prohibits degradation, and causes storage, of lysosomal glycogen in predominantly cardiac and skeletal muscle. Early and late onset forms of GSD II can be distinguished, which has been attributed to varying degrees of residual acid ␣-glucosidase activity (16, 24). The infantile form shows no residual activity, and patients suffering from this condition present themselves with hypotonia and hypertrophic cardiomegaly within a few months after birth. They usually die of cardiorespiratory failure before they reach the age of 1 yr (13, 24). Milder forms have residual activities up to 25% of normal values and are typically characterized by skeletal muscle weakness without involvement of the heart. Ultimately, these patients become wheelchair-bound and dependent on artificial ventilation.
POMPE'S DISEASE or glycogen storage disease type II (GSD II) is an autosomal recessive and often fatal disease caused by mutations in the acid ␣-glucosidase gene (16) . The resultant deficiency of acid ␣-glucosidase activity prohibits degradation, and causes storage, of lysosomal glycogen in predominantly cardiac and skeletal muscle. Early and late onset forms of GSD II can be distinguished, which has been attributed to varying degrees of residual acid ␣-glucosidase activity (16, 24) . The infantile form shows no residual activity, and patients suffering from this condition present themselves with hypotonia and hypertrophic cardiomegaly within a few months after birth. They usually die of cardiorespiratory failure before they reach the age of 1 yr (13, 24) . Milder forms have residual activities up to 25% of normal values and are typically characterized by skeletal muscle weakness without involvement of the heart. Ultimately, these patients become wheelchair-bound and dependent on artificial ventilation.
Recently, knockout (KO) mouse models of GSD II have been developed (2) (3) (4) 22) . In the present study, we investigated the cardiac phenotype of our mouse model, in terms of cardiac mass, left ventricular (LV) geometry, and LV contractile function and reserve to assess its usefulness for investigations into the pathophysiology of this disease and assessment of novel therapies.
METHODS
All experiments were conducted in accordance with the "Guiding Principles in the Care and Use of Animals" as approved by the American Physiological Society and with prior approval of the Animal Care Committee of the Erasmus University Rotterdam.
Experimental Design
In the first part of the study we investigated the LV morphological, geometrical, and contractile functional consequences of ␣-glucosidase deficiency in ketamine-xylazine anesthetized mice. To determine whether the low heart rates (250-300 beats/min) that were produced by ketamine-xylazine anesthesia influenced our results on LV contractile function, we repeated the hemodynamic measurements in the second part of the study in isoflurane-anesthetized mice, in which heart rates (450-600 beats/min) approximated the values we (450-550 beats/min; unpublished data from our laboratory) and others (478 Ϯ 12 beats/min; Ref. 21 ) observe under awake conditions. Article published online before print. See web site for date of publication (http://physiolgenomics.physiology.org).
Experimental Groups
The acid ␣-glucosidase-deficient KO mice in this study were obtained by targeted disruption of the acid ␣-glucosidase gene in embryonic stem cells as previously described (2) . For the first part of the study, we used seven KO mice of which three had been crossed back into FVB background for six generations and four into C57Bl/6 background for three generations. Eight wild-type (WT) littermates served as controls. Five of these were FVB, and three were C57Bl/6. FVB mice were between 10 and 14 mo of age, and C57Bl/6 mice were between 20 and 24 mo of age. For the second part of the study, we used three KO mice which had been crossed back into C57Bl/6 background for 10 generations, while 5 WT littermates served as controls. Mice were between 16 and 20 mo of age. The night before the experiment, mice were starved to deplete cytoplasmic glycogen (2, 4) .
Experimental Protocol
Echocardiography. In the first part of the study, mice were weighed, anesthetized with ketamine (25 mg/kg ip) and xylazine (5 mg/kg ip), and hair from the left side of the thorax was shaved off. A tracheotomy was performed, a polyethylene tube (ID/OD, 0.58/0.80 mm) was inserted and secured with a suture to prevent leakage of air, and the mouse was artificially ventilated at a rate of 60-70 strokes/min (rodent ventilator; Harvard, Hilliston, MA). Electrocardiography (ECG) leads were connected, and the mouse was submerged in a water bath of 37°C, ϳ2 cm below the water surface. Echocardiograms were made with the HP Sonos 5500 echo device (Hewlett-Packard, Andover, MA) using a 12-MHz probe. Images of the short axis were obtained in 2D-and M-mode settings, with simultaneous recordings of ECG. All measurements were obtained while artificial ventilation was temporarily turned off.
Hemodynamic measurements. Following echocardiography, mice were removed from the water basin and placed on a heating pad. Body temperature was monitored via a rectal thermometer and maintained at 37°C. After receiving a second intraperitoneal bolus of anesthetics (25 mg/kg ketamine and 5 mg/kg xylazine) mice were instrumented for hemodynamic measurements. For this purpose, a polyethylene catheter (PE-10) was inserted into the right carotid artery and advanced into the aortic arch to measure aortic blood pressure. An identical catheter was introduced into the right external jugular vein and advanced into the superior caval vein for infusion of dobutamine. After a thoracotomy was performed through the 4th left intercostal space, the pericardium was opened and the heart was exposed. Subsequently, a 2-French Millar microtipped manometer (calibrated prior to each experiment with a mercury manometer) was inserted into the LV via the apex to measure LV pressure and its first derivative, LV dP/dt (obtained via electronic differentiation).
Following a 15-min stabilization period, baseline recordings were obtained of aortic blood pressure, heart rate, LV pressure, and LV dP/dt. A continuous intravenous infusion of dobutamine (concentration 10 g/ml) was started at 2 g ⅐ kg Ϫ1 ⅐ min Ϫ1 , and the rate of infusion was increased at 3-min intervals until LV dP/dtmax did not further increase. At peak responses to dobutamine all measurements were repeated.
Hemodynamic measurements under isoflurane anesthesia. In the second part of the study, mice were ventilated with a mixture of O 2 and N2O (1/2, vol/vol) to which isoflurane (1.5-2.0 vol%) was added. The surgical instrumentation and experimental protocol were identical to that in the ketaminexylazine anesthetized mice of the first part of the study, but we now used a 1.4-French Millar microtipped manometer to measure LV pressure. We observed in two pilot experiments in C57Bl/6 WT mice under isoflurane anesthesia that dobutamine produced a decrease in blood pressure, whereas it had no effect on heart rate, confirming previous observations by Hoit et al. (17) . Therefore, we chose to infuse norepinephrine (concentration 20 g/ml) starting at 2 g ⅐ kg Ϫ1 ⅐ min Ϫ1 iv and doubled the infusion rate every 3 min until LV dP/dtmax did not increase further.
Biochemistry and Morphology
At the conclusion of each experiment, the heart was excised and the atria were removed. The right ventricle (RV) and LV were separated, weighed, and freeze dried for the determination of dry weights and, in the first part of the study, for determination of acid ␣-glucosidase activity and glycogen content. In addition, samples were also obtained from the musculus quadriceps femoris and the liver to measure acid ␣-glucosidase activity and glycogen content. The atria and another sample from the musculus quadriceps femoris were fixed in glutaraldehyde (4%) and embedded in glycolmethacrylate, and histological sections of 4 m were stained with hematoxylin azofloxin and periodic acid-Schiff. Tail DNA was extracted to verify the genotype by PCR (2) .
Atria, muscle, and liver samples were homogenized in PBS, using an Ultra Turrax (TP18-10, 20,000 rpm; 170 W; see Ref.
2). Large debris was removed after centrifugation at 10,000 g for 15 min. The supernatant was sonicated on ice for two 10-s periods at an amplitude of 10 m, then analyzed for total protein concentration with the bicinchoninic acid protein assay (BCA; Pierce, Rockford, IL) and acid ␣-glucosidase activity with 4-methylumbelliferyl-␣-D-glucopyranoside (4MU) as substrate at a pH of 4.0. The glycogen content was measured after dialysis of the sample to remove cytoplasmic glucose, as previously described (2, 28) .
Data Analysis
Echocardiography data were collected on an optical disk and stored for offline analysis. LV diameters at end-diastole (EDD) and end-systole (ESD) as well as the ED and ES thickness of the LV posterior wall were measured from the M-mode images using Clemex Vision software package (Clemex Technologies, Longueuil, Quebec, Canada). Five consecutive beats were analyzed in triplicate and averaged. LV absolute shortening (EDD Ϫ ESD) and fractional shortening [(EDD Ϫ ESD)/EDD ϫ 100%] were calculated. Hemodynamic data were recorded and digitized using an online four-channel data acquisition program (ATCODAS; Dataq Instruments, Akron, OH) for postacquisition offline analysis with a program written in MATLAB (Mathworks, Natick, MA). Fifteen consecutive beats were selected for determination of heart rate, LV peak systolic and end-diastolic pressures, diastolic aortic pressure, and the maximum rates of rise (LVdP/dt max) and fall (LVdP/dtmin) of LV pressure. In addition, the time constant () of LV pressure decay, an index of early LV relaxation, was computed as described earlier (11) .
Statistical analysis of anatomical and echocardiography data was performed using unpaired t-test or McNemar test as appropriate. Analysis of hemodynamic data was performed using two-way ANOVA followed by post hoc testing with paired and unpaired t-test or signed rank test and McNemar test, as appropriate. Statistical significance was accepted when P Ͻ 0.05 (two-tailed).
RESULTS

Biochemistry and Morphology
Biochemistry. The acid ␣-glucosidase activity in the heart of WT mice that were studied under ketaminexylazine anesthesia was 12.6 Ϯ 2.6 nmol 4MU ⅐ h Ϫ1 ⅐ mg protein Ϫ1 but only 1.0 Ϯ 0.1 nmol 4MU ⅐ h Ϫ1 ⅐ mg protein Ϫ1 in KO mice. Consequently, the glycogen content in the heart was high in KO mice (330 Ϯ 30 mg/ mg protein in 10-to 14-mo-old FVB KO mice, and 3,260 Ϯ 980 mg/mg protein in 20-to 24-mo-old C57Bl/6 KO mice) and very low in WT mice (1.8 Ϯ 0.9 mg/mg protein; Fig. 1) .
Microscopy. Atria and skeletal muscle samples from all KO mice had periodic acid-Schiff-positive arrays of glycogen-filled lysosomes and lacework patterns resulting from lysosomal rupture and loss of content, as previously reported (4) . Some of the WT mice showed little cytoplasmic glycogen content.
Macroscopy. The wet weight of the heart (HW) was on average 44% higher in KO compared with WT mice (P Ͻ 0.05), due to increases in both LV weight (LVW, 47%, P Ͻ 0.05) and RV weight (RVW, 31%, P ϭ 0.08) ( Table 1) . Similar increments were observed in the dry weights of the whole heart, LV, and RV (all P Ͻ 0.05). Since total body weight (BW) was on average 30% lower in KO than in WT mice, it follows that the HW/BW, LVW/BW, and RVW/BW were almost doubled in KO compared with WT mice. KO mice with the highest glycogen content had the highest LVW/BW ratio (Fig. 1) .
Echocardiography
The LV of KO mice was characterized by an increased wall thickness (83%, P Ͻ 0.05) and a modest encroachment of the LV lumen, reflected by an average 22% reduction in end-diastolic LV luminal diameter (P Ͻ 0.05) ( Table 2 ). There were no significant differences between KO and WT mice in absolute (0.74 Ϯ 0.05 vs. 0.99 Ϯ 0.12 mm) or fractional (34 Ϯ 3 vs. 30 Ϯ 4%) LV diameter shortening. LV wall thickness showed a good correlation (r 2 ϭ 0.66, P Ͻ 0.01) with the LVW/BW, whereas the LV lumen diameter did not correlate with LVW/BW (Fig. 2) .
Hemodynamics
Baseline. Under baseline conditions, LV dP/dt max and diastolic arterial pressure were lower in KO than in WT mice. The trends toward a lower heart rate, a lower diastolic arterial pressure, and a lower LV systolic pressure in KO mice and the trend toward the increase in in these mice did not reach levels of statistical significance (Table 3) .
Pooling of all individual data points from KO and WT mice revealed an inverse correlation between LVW/BW and LV dP/dt max (r 2 ϭ 0.76), suggesting that LV contractility becomes more impaired with increased LVW (Fig. 3) . However, since there was also an inverse correlation between LVW/BW and diastolic arterial pressure (r 2 ϭ 0.74), the lower diastolic arterial pres- sure in KO mice may have contributed to the lower LV dP/dt max under basal conditions. Indeed, diastolic pressure and LV dP/dt max were correlated (r 2 ϭ 0.76, P Ͻ 0.05), and stepwise regression analysis revealed that diastolic arterial pressure was an independent predictor of LV dP/dt max (P Ͻ 0.05). Similarly, there was a positive correlation between LVW/BW and LV dP/dt min (r 2 ϭ 0.85), but also between LVW/BW and LV systolic pressure (r 2 ϭ 0.76). The lower LV systolic pressure may have contributed to the lower maximum rate of fall of LV pressure, as is suggested by the close correlation between LV systolic pressure and LV dP/dt min observed during univariate regression analysis (r 2 ϭ 0.96, P Ͻ 0.05). In addition, stepwise regression analysis showed LV systolic pressure to be an independent determinant of LV dP/dt min (P Ͻ 0.05). The time constant , which describes the rate of relaxation during early diastole, was considerably higher in KO mice with the highest LVW/BW, suggesting impaired LV relaxation in these mice (Fig. 3) . In contrast, LV enddiastolic pressures were not increased in KO compared with WT mice. Dobutamine. Intravenous infusion of dobutamine increased heart rate, diastolic arterial pressure, LV systolic pressure, LV dP/dt max , and LV dP/dt min , and decreased , but had no effect on LV end-diastolic pressure in both WT and KO mice (Table 3 ). There were no differences in the responses to dobutamine in KO and WT mice. During dobutamine infusion, the inverse correlation between LVW/BW and LV dP/dt max was maintained (r 2 ϭ 0.62), but the inverse correlation between LVW/BW and diastolic arterial pressure was not significant (Fig. 3) , indicating that the lower LV dP/dt max during dobutamine was principally the result of a lower global LV contractility. During dobutamine infusion, the relation between LVW/BW and LV dP/ dt min was maintained, but was no longer different in KO and WT mice. The doses of dobutamine needed to produce maximal increases in LV dP/dt max in KO and WT mice were 9 Ϯ 2 and 8 Ϯ 2 g ⅐ kg Ϫ1 ⅐ min Ϫ1 , respectively.
Hemodynamics During Isoflurane Anesthesia
Baseline hemodynamics. Heart rate and LV dP/dt max were significantly higher during isoflurane anesthesia (Table 4 ) than during ketamine-xylazine anesthesia (Table 3) . Despite these differences in hemodynamics produced by the two anesthesia regimens, heart rate (471 Ϯ 28 vs. 581 Ϯ 23 beats/min) and LV dP/dt max (5,400 Ϯ 670 vs. 8,250 Ϯ 710 mmHg/s) were again lower in KO than in WT mice (both P Ͻ 0.05), whereas diastolic arterial blood pressure (64 Ϯ 6 vs. 58 Ϯ 5 mmHg) and LV systolic pressure (94 Ϯ 10 vs. 122 Ϯ 14 mmHg) were not different. In these animals, ratios of HR/BW, LVW/BW, and RVW/BW were, respectively, Values are means Ϯ SE; n ϭ number of observations. HR, heart rate; DAP, diastolic arterial blood pressure; LVSP, left ventricular systolic blood pressure; LVEDP, left ventricular end diastolic blood pressure; LV dP/tmax, maximum rate of rise of left ventricular pressure; LV dP/dtmin, maximum rate of fall of LV pressure; , time constant of early diastolic LV pressure decay. * P Ͻ 0.05 vs. wildtype mice. † P Ͻ 0.05 vs. baseline. Similar to the study under ketamine-xylazine anesthesia, there were correlations between LVW/BW and LV dP/dt max (r 2 ϭ 0.79), LVW/BW and LV dP/dt min (r 2 ϭ 0.52), and LVW/BW and (r 2 ϭ 0.52; all P Ͻ 0.05) in the isoflurane-anesthetized mice (Fig. 4) . There was also an inverse correlation between LVW/BW and heart rate (r 2 ϭ 0.61), suggesting that the lower heart rate in KO mice may have contributed to the aforementioned correlations. Univariate regression analysis showed a correlation between heart rate and LV dP/ dt max (r 2 ϭ 0.36, P ϭ 0.07) and (r 2 ϭ 0.47, P Ͻ 0.05), but not LV dP/dt min (r 2 ϭ 0.10), under basal conditions. However, stepwise regression analysis showed that heart rate did not contribute significantly to the prediction of LV dP/dt max (P ϭ 0.55), LV dP/dt min (P ϭ 0.48), or (P ϭ 0.27), in addition to LVW/BW.
Norepinephrine. Intravenous infusion of norepinephrine increased heart rate, diastolic arterial pressure, LV systolic pressure, and LV dP/dt max in both WT and KO mice (Table 4 ). There were no significant differences in the responses to norepinephrine in KO and WT mice, with the exception of heart rate which increased only in the KO mice, so that heart rates were 
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CARDIAC PHENOTYPE OF ACID ␣-GLUCOSIDASE KNOCKOUT MICE no longer different in KO and WT mice. During norepinephrine infusion, the inverse correlation between LVW/BW and LV dP/dt max became even more pronounced (r 2 ϭ 0.62), in the absence of a significant relation between LVW/BW and heart rate, diastolic arterial pressure, or LV systolic pressure (Fig. 4) , indicating that the lower LV dP/dt max during norepinephrine was principally the result of a lower global LV contractility. During norepinephrine infusion, the relation between LVW/BW and LV dP/dt min was maintained. Similar to the ketamine-xylazine study, was again no longer different in KO and WT mice during norepinephrine infusion. The doses of norepinephrine needed to produce the maximal responses in LV dP/ dt max in KO and WT mice were 11 Ϯ 3 and 11 Ϯ 2 g ⅐ kg Ϫ1 ⅐ min Ϫ1 , respectively.
DISCUSSION
The major findings of the present study are that 1) mice lacking acid ␣-glucosidase activity show an increase in cardiac mass involving both LV and RV, 2) the increase in LVW is associated with a marked increase in LV wall thickness and encroachment of the LV lumen, and 3) the degree of LV mass increase is inversely correlated with the loss of maximal attainable LV global contractility during ␤-adrenergic stimulation.
Cardiac Mass
Qualitative descriptions of enlarged hearts have been previously reported in naturally occurring GSD II in turkey (9), sheep (19), dog (29) , and a subpopulation of shorthorn cattle (18) . HW, LVW, and RVW were reported in only one study in two calves, at an age of 3-7 mo, in which the HW/BW ratio had tripled compared with normal, due to more than a doubling of LVW and a quadrupling of RVW (25) . In the present murine study, we observed an increase in relative heart weight (HW) of up to 160%, due to a 166% increase in relative LVW and a 130% increase in relative RVW. We observed a strong correlation between glycogen storage in the heart and the relative LVW. In ϳ10-to 14-mo-old FVB KO mice, the average glycogen content was around 300 mg/mg protein, whereas in 20-to 24-mo-old C57Bl/6 KO mice glycogen content was between 2,200 and 5,200 mg/mg protein, resulting in a 40% increase in relative LVW in 10-to 14-mo-old FVB and a 166% increase in 20-to 24-mo-old C57Bl/6 KO mice. In the three additional 16-to 18-mo-old C57Bl/6 KO mice, relative LVW was 98% higher than in littermate WT mice. Together, these findings suggest that glycogen continues to accumulate in the murine heart up to 2 yr of age. The increase in relative HW in mice (up to 160% at 24 mo ϩ 3 wk gestation time) approximates that in calves (up to 200% at 3.7 mo ϩ 6 mo gestation time), but is significantly less than the increase in humans (up to 350% at 3-10 mo ϩ 9 mo gestation time). Interestingly, the increase in relative HW in humans appears to level off after ϳ3 mo after birth, as HWs are ϳ3 times normal at 2 wk of age (n ϭ 8) and 4.5 times normal at 3 mo (n ϭ 8), but with no significant further increase between 3 and 10 mo (n ϭ 40) (1, 8, 12, 20) . In contrast, glycogen continues to accumulate in the murine heart between 10 mo and 24 mo of age.
LV Wall Thickness and Lumen Diameter
Data on alterations in LV geometry in infants with GSD II have been obtained during autopsy and revealed increases in wall thickness of 6-10 mm in the LV (normal range 2-4 mm) a few weeks after birth, whereas in children who died at ϳ2 yr of age, wall thickness had increased up to a maximum of 25 mm in the LV (normal range 4-6 mm) (12) . More recent echocardiography studies have generally reported severe cardiomegaly with extremely thick ventricular walls and relatively normal atria (7) . In most cases hypertrophy of the LV free wall and septum is more pronounced than in the RV (14) . Another typical echocardiography finding is the encroachment of the LV lumen as was found in two girls of 6-7 mo of age (14, 23) . Encroachment of the lumen may become so severe that outflow tract obstruction and inflow impairment develop (12, 23, 27) .
The present study is the first to describe the echocardiography abnormalities in an animal model of GSD II. The main feature of the echocardiography findings was an increased LV wall thickness up to 200% of WT mice together with a modest encroachment of the LV lumen, which corresponds well with the echocardiography findings in infantile GSD II in humans. The degree of encroachment was somewhat variable and did not occur in all KO animals ( Fig. 1) but could reflect the onset of LV failure with resulting LV dilation. 
LV Contractile Function and Reserve
In contrast to the well-described anatomic and echocardiography abnormalities in patients with GSD II, there is surprisingly little information on LV contractile function in GSD II. De Dominicis et al. (10) reported normal ejection fractions (70% and 68%) measured with echocardiography in two 6-mo-old patients. Bulkley and Hutchins (7) also reported a normal ejection fraction (Ͼ70%), measured with LV angiography, in a 5-mo-old girl. In two other case reports (children up to 9 mo of age), invasive assessment of LV function using cardiac catheterization demonstrated normal LV filling pressures (2-3 mmHg) , in the presence of severe cardiomegaly (12, 15) . In another case report (4 mo of age) normal LV hemodynamics and cardiac index were observed, although early diastolic pressure was elevated with a restrictive LV filling pattern (5). In contrast, markedly elevated LV filling pressures (up to 20 mmHg) and a depressed cardiac index (2.44 l ⅐ min Ϫ1 ⅐ m
Ϫ2
) were found in a 4-mo-old child (26) . In all these case studies, children invariably developed progressive clinical heart failure and died within 2 mo after catheterization. Unfortunately, in none of these studies were LV contractility and LV contractile reserve determined.
The present murine study also shows a normal fractional LV diameter shortening in KO compared with WT mice under basal conditions. However, LV function was not normal, as we observed decreases in LV dP/ dt max , under basal conditions and, in particular, during ␤-adrenergic stimulation with either dobutamine or norepinephrine infusion. The additional experiments with norepinephrine were performed during isoflurane anesthesia to exclude that the low heart rates and LV dP/dt max values observed during ketamine-xylazine anesthesia influenced the results (21) . In addition, we used a 1.4-French microtipped manometer in these experiments to further minimize mechanical perturbation of LV volume and contractile performance. The maximal attainable LV dP/dt max correlated well with the increase in LVW in both series of experiments, thus independent of the anesthesia regimen or size of the LV catheter, suggesting that at more severe stages of the disease LV function becomes impaired. However, from the present study it also becomes clear that the KO animals are not yet in severe cardiac failure. This is suggested by the normal fractional LV diameter shortening and by the comparable doses of both dobutamine and norepinephrine needed to elicit maximal responses of LV dP/dt max in KO compared with WT mice, suggesting normal ␤-adrenergic receptor sensitivity (6) . Moreover, although the less negative LV dP/dt min and increase in in KO compared with WT mice indicate a slight impairment of early diastolic function, which is in close agreement with human data (5), the normal levels of LV filling pressure in KO compared with WT mice also suggest the absence of overt diastolic dysfunction.
Conclusions
The present study demonstrates that the acid ␣-glucosidase KO mouse model is characterized by increased cardiac mass, which is associated with an increased LV free wall thickness and with encroachment of the LV lumen, as well as a lower global LV contractility. These manifestations of cardiomegaly and LV dysfunction, although not as overt, parallel the human conditions of early onset GSD II and make these mice a suitable model for further investigation of pathophysiology and novel therapies of infantile Pompe's disease.
